Abstract
The effects of rivastigmine versus placebo in Parkinson's disease dementia (PDD) patients with elevated or normal/low plasma homocysteine were determined. In this prospective analysis of a 24‐week, randomly assigned, placebo‐controlled study of rivastigmine in PDD, subpopulations comprised patients with plasma homocysteine ≥14 μmol/L (elevated) or P < 0.01), and significant treatment differences on secondary outcomes. Rivastigmine‐ and placebo‐treated hyperhomocysteinemic patients (16.5% and 14.6%) discontinued the study because of AEs. Patients with normal/low homocysteine showed no treatment differences on primary or secondary outcomes (1.4 on the ADAS‐cog and 0.1 on ADCS‐CGIC, both P = ns); 16.7% and 10.3% rivastigmine‐ and placebo‐treated patients discontinued because of AEs. Elevated homocysteine was associated with greater rivastigmine treatment differences than normal/low homocysteine. © 2008 Movement Disorder Society

This publication has 31 references indexed in Scilit: